Wietzke-Braun Perdita, Schindler Christian, Raddatz Dirk, Braun Felix, Armbrust Thomas, Nolte Wilhelm, Ramadori Giuliano
Abteilung für Gastroenterologie und Endokrinologie, Zentrum Innere Medizin, Georg-August-Universität, Göttingen, Germany.
Eur J Gastroenterol Hepatol. 2004 Apr;16(4):389-95. doi: 10.1097/00042737-200404000-00004.
Patients with non-resectable liver metastases of colorectal cancer have poor prognosis and are mainly treated by palliative chemotherapy. Laser interstitial thermo-therapy is an innovative minimal invasive procedure for local tumour destruction within solid organs. The aim of the study was to investigate quality of life and outcome of ultrasound-guided laser interstitial thermo-therapy (US-LITT) in patients with liver metastases of colorectal cancer.
In this prospective non-randomized study, 45 patients with liver metastases of colorectal cancer were palliatively treated by US-LITT. Patient survival was analysed by the Kaplan-Meier method and the quality of life by questionnaire C30 of the European Organisation for Research and Treatment of Cancer before, and 1 week, 1 month, and 6 months after initiation of US-LITT.
Median survival after initiation of US-LITT was 8.5 +/- 0.7 months with a range of 1.5-18 months. Body weight was constant 1 month after US-LITT. In the multivariate analyses, quality-of-life symptoms and functioning scales did not deteriorate in patients alive at 6 months after initiation of US-LITT. Univariate analyses outlined a significant increase of the pain subscale before and at 1 week after US-LITT.
This study first describes the quality of life in patients with liver metastases of colorectal cancer treated by US-LITT. Potential benefits of the minimal invasive procedure could be prolonged survival time by preserved quality of life, but this first impression needs to be verified in a comparative study.
不可切除的结直肠癌肝转移患者预后较差,主要接受姑息化疗。激光间质热疗是一种用于实体器官内局部肿瘤破坏的创新性微创方法。本研究的目的是调查超声引导下激光间质热疗(US-LITT)治疗结直肠癌肝转移患者的生活质量和疗效。
在这项前瞻性非随机研究中,45例结直肠癌肝转移患者接受了US-LITT姑息治疗。采用Kaplan-Meier法分析患者生存率,并在US-LITT开始前、开始后1周、1个月和6个月通过欧洲癌症研究与治疗组织的C30问卷分析生活质量。
US-LITT开始后的中位生存期为8.5±0.7个月,范围为1.5 - 18个月。US-LITT后1个月体重保持稳定。在多变量分析中,US-LITT开始后6个月存活的患者生活质量症状和功能量表未恶化。单变量分析显示,US-LITT前及后1周疼痛子量表显著增加。
本研究首次描述了接受US-LITT治疗的结直肠癌肝转移患者的生活质量。这种微创方法的潜在益处可能是通过保持生活质量来延长生存时间,但这一初步印象需要在一项比较研究中得到验证。